Recursion Pharmaceuticals, Inc. (RXRX) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
RXRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RXRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -62.0% | -867.9% | -863.4% |
| 2024 | 23.1% | -814.1% | -788.0% |
| 2023 | 2.9% | -797.8% | -747.7% |
| 2022 | -21.7% | -619.3% | -603.5% |
| 2021 | 100.0% | -1827.8% | -1864.8% |
Download Data
Export RXRX earnings history in CSV or JSON format
Free sign-in required to download data
Recursion Pharmaceuticals, Inc. (RXRX) Earnings Overview
As of May 8, 2026, Recursion Pharmaceuticals, Inc. (RXRX) reported trailing twelve-month net income of -$560M, reflecting +14.8% year-over-year growth. The company earned $-1.06 per diluted share over the past four quarters, with a net profit margin of -863.4%.
Looking at the long-term picture, RXRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$63M in fiscal 2019.
Recursion Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SDGR (-$103M net income, -40.4% margin), ABCL (-$146M net income, -194.9% margin), RLAY (-$273M net income, -1800.6% margin), RXRX has room to improve margins relative to the peer group. Compare RXRX vs SDGR →
RXRX Earnings vs Peers
Earnings metrics vs comparable public companies
RXRX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$645M | -39.1% | -$648M | $-1.44 | -863.4% | -867.9% |
| 2024 | -$464M | -41.3% | -$479M | $-1.69 | -788.0% | -814.1% |
| 2023 | -$328M | -37.0% | -$350M | $-1.58 | -747.7% | -797.8% |
| 2022 | -$239M | -28.4% | -$246M | $-1.36 | -603.5% | -619.3% |
| 2021 | -$186M | -114.3% | -$183M | $-1.05 | -1864.8% | -1827.8% |
| 2020 | -$87M | -39.2% | -$85M | $-0.52 | -2549.3% | -2479.2% |
| 2019 | -$63M | - | -$62M | $-0.37 | -3654.3% | -3649.4% |
See RXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRXRX — Frequently Asked Questions
Quick answers to the most common questions about buying RXRX stock.
Is RXRX growing earnings?
RXRX EPS stands at $-1.06, with +14.8% growth matching the 5-year CAGR of N/A. TTM net income is $-560M. Earnings trajectory remains consistent.
What are RXRX's profit margins?
Recursion Pharmaceuticals, Inc. net margin is -863.4%, with operating margin at -867.9%. Below-average margins reflect competitive or cost pressures.
How consistent are RXRX's earnings?
RXRX earnings data spans 2019-2025. The current earnings trend is +14.8% YoY. Historical data enables comparison across business cycles.